Literature DB >> 6117011

Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome.

K G Lloyd, O Hornykiewicz, L Davidson, K Shannak, I Farley, M Goldstein, M Shibuya, W N Kelley, I H Fox.   

Abstract

Different brain regions were removed post mortem from three patients with the Lesch-Nyhan syndrome and were examined for alterations in hypoxanthine-guanine phosphoribosyl transferase (HGPRT), adenine phosphoribosyl transferase, and biochemical indexes of norepinephrine, dopamine, serotonin, gamma-aminobutyric acid (GABA), and acetylcholine neuron function, as compared with age-matched controls. The level of HGPRT activity in the material from patients with the Lesch-Nyhan syndrome was less than 1 per cent of control levels, whereas adenyl phosphoribosyl transferase was not significantly altered. All biochemical aspects of the function of dopamine-neuron terminals in the striatum (except dihydroxyphenylacetic acid levels) were decreased to 10 to 30 per cent of the control values. Serotonin and 5-hydroxyindoleacetic acid levels were increased, striatal choline acetyltransferase levels were low, and striatal glutamic acid decarboxylase and guanylate cyclase activities were unaltered. The disruption of the balance between the functions of GABA, dopamine, and acetylcholine neurons in the extrapyramidal system probably accounts for some of the symptoms observed in the Lesch-Nyhan syndrome (e.g., choreoathetosis).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6117011     DOI: 10.1056/NEJM198111053051902

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  59 in total

1.  Individual differences in vulnerability for self-injurious behavior: studies using an animal model.

Authors:  Amber M Muehlmann; Jennifer A Wilkinson; Darragh P Devine
Journal:  Behav Brain Res       Date:  2010-10-23       Impact factor: 3.332

Review 2.  Convergent mechanisms in etiologically-diverse dystonias.

Authors:  Valerie B Thompson; H A Jinnah; Ellen J Hess
Journal:  Expert Opin Ther Targets       Date:  2011-12-03       Impact factor: 6.902

3.  Intrastriatal injection of hypoxanthine reduces striatal serotonin content and impairs spatial memory performance in rats.

Authors:  Caren Serra Bavaresco; Fabria Chiarani; Eduardo Duringon; Marcelo Machado Ferro; Cláudio Da Cunha; Carlos Alexandre Netto; Angela Terezinha de Souza Wyse
Journal:  Metab Brain Dis       Date:  2007-01-13       Impact factor: 3.584

4.  Dopamine agonist-induced stereotypic grooming and self-mutilation following striatal dopamine depletion.

Authors:  S L Hartgraves; P K Randall
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

5.  Reduced urinary serotonin excretion after intake of high doses of hypoxanthine.

Authors:  H Manzke; H Gustmann
Journal:  Eur J Pediatr       Date:  1989-01       Impact factor: 3.183

6.  Consequences of impaired purine recycling on the proteome in a cellular model of Lesch-Nyhan disease.

Authors:  Eric B Dammer; Martin Göttle; Duc M Duong; John Hanfelt; Nicholas T Seyfried; H A Jinnah
Journal:  Mol Genet Metab       Date:  2015-03-05       Impact factor: 4.797

7.  Caffeine-induced changes in the composition of the free amino acid pool of the cerebral cortex.

Authors:  M Portolés; M D Miñana; A Jordá; S Grisolía
Journal:  Neurochem Res       Date:  1985-07       Impact factor: 3.996

Review 8.  Clinical and biochemical aspects of uric acid overproduction.

Authors:  J García Puig; F A Mateos
Journal:  Pharm World Sci       Date:  1994-04-15

9.  Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo.

Authors:  D F Wong; J C Harris; S Naidu; F Yokoi; S Marenco; R F Dannals; H T Ravert; M Yaster; A Evans; O Rousset; R N Bryan; A Gjedde; M J Kuhar; G R Breese
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

10.  A model of behavioral treatments for self-mutilation behavior in Lesch-Nyhan syndrome.

Authors:  Eric A Zilli; Michael E Hasselmo
Journal:  Neuroreport       Date:  2008-03-05       Impact factor: 1.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.